ValuEngine Lowers Intellia Therapeutics (NTLA) to Sell

ValuEngine downgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a sell rating in a research note released on Wednesday, November 15th.

NTLA has been the topic of several other research reports. Credit Suisse Group lifted their price objective on Intellia Therapeutics from $24.00 to $28.00 and gave the stock an outperform rating in a report on Friday, November 3rd. Jefferies Group set a $42.00 price target on Intellia Therapeutics and gave the company a buy rating in a report on Tuesday, October 31st. Leerink Swann boosted their price target on Intellia Therapeutics from $29.00 to $37.00 and gave the company an outperform rating in a report on Tuesday, October 31st. They noted that the move was a valuation call. Wedbush restated an ourperform rating and set a $25.00 price target (down previously from $29.00) on shares of Intellia Therapeutics in a report on Wednesday, September 27th. Finally, Zacks Investment Research upgraded Intellia Therapeutics from a sell rating to a hold rating in a report on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. The stock has an average rating of Hold and an average price target of $30.17.

Intellia Therapeutics (NTLA) opened at $23.00 on Wednesday. Intellia Therapeutics has a twelve month low of $10.83 and a twelve month high of $33.34.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. The firm had revenue of $7.30 million for the quarter, compared to the consensus estimate of $5.83 million. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The company’s quarterly revenue was up 49.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.22) earnings per share. equities research analysts anticipate that Intellia Therapeutics will post -1.68 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP grew its holdings in shares of Intellia Therapeutics by 28.9% during the 3rd quarter. GSA Capital Partners LLP now owns 73,100 shares of the company’s stock worth $1,817,000 after acquiring an additional 16,400 shares during the period. Neuberger Berman Group LLC grew its holdings in shares of Intellia Therapeutics by 23.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 60,915 shares of the company’s stock worth $1,514,000 after acquiring an additional 11,398 shares during the period. Granahan Investment Management Inc. MA grew its holdings in shares of Intellia Therapeutics by 7.0% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 286,144 shares of the company’s stock worth $7,111,000 after acquiring an additional 18,784 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in shares of Intellia Therapeutics by 34.7% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 57,492 shares of the company’s stock worth $1,429,000 after acquiring an additional 14,818 shares during the period. Finally, GMT Capital Corp bought a new stake in shares of Intellia Therapeutics in the 3rd quarter worth approximately $8,214,000. Hedge funds and other institutional investors own 49.49% of the company’s stock.

WARNING: This piece of content was originally published by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://weekherald.com/2017/12/04/valuengine-lowers-intellia-therapeutics-inc-ntla-to-sell.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply